US Graves’ disease market is growing at a CAGR of around 4.0% during the forecast period. The US Grave’s disease market is showing significant growth due to funding for autoimmune disease researches, and the increasing prevalence of hyperthyroidism in the region. In addition, significant rise in the prevalence of autoimmune disease is also expected to propel the growth of the US Graves’ disease market. According to the American Autoimmune Related Diseases Association, Inc. (AARDA), the number of Americans suffer from autoimmune disease is 50 million. This is approximately 20% of the total population or 1 in 5 people suffer from autoimmune disease. 75% of people that are affected with autoimmune disease, about 30 million are women.
Visit for Global Graves Disease Market Report at: https://www.omrglobal.com/industry-reports/graves-disease-market
Furthermore, as per AARDA, NIH invests $591 million on autoimmune disease research. NIH supports companies in the development of therapies for the treatment of Grave’s. For instance, in December 2017, EpiVax, Inc., a US-based biotech firm declared the latest program for novel antigen-specific therapies. The funding was provided by NIH for development of the therapy. This approach may have applications in various autoimmune diseases.
Moreover, hyperthyroidism is the most common disease in the US. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), estimated 1.2% of people in the US have hyperthyroidism. The people that have other health problems, such as type 1 diabetes, primary adrenal insufficiency and pernicious anemia are likely to develop hyperthyroidism. The most common cause of hyperthyroidism is Grave’s disease. According to Beyond Type 1, the prevalence of hypothyroidism due to Hashimoto’s thyroiditis is anticipated to range from 4 to 19% of people with type 1 diabetes. The significant increase in incidences of type-1 diabetes increases the possibility of having Grave’s disease and thereby contributing to the growth of the US Graves’ disease market.
Research Methodology
The market study of the US Graves’ disease market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. US Graves’ Disease by Diagnosis
5.1.1. Ultrasound
5.1.2. Imaging Tests
5.1.3. Radioactive Iodine Uptake
5.1.4. Blood Sample
5.2. US Graves’ Disease by Treatment
5.2.1. Anti- Thyroid Medication
5.2.2. Radioactive Iodine Therapy
5.2.3. Surgery
6. Company Profiles
6.1. Abbott Laboratories Inc.
6.2. Allergan PLC
6.3. Eli Lilly and Co.
6.4. GlaxoSmithKline PLC
6.5. Johnson & Johnson
6.6. Macleods Pharmaceuticals Ltd.
6.7. Merck & Co. Inc.
6.8. Mylan NV
6.9. Novartis International AG
6.10. Pfizer Inc.
6.11. Sanofi SA
6.12. Takeda Pharmaceutical Co. Ltd.
1. US GRAVES’ DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2018-2025 ($ MILLION)
2. US GRAVES’ DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
1. US GRAVES’ DISEASE MARKET SHARE BY DIAGNOSIS, 2018 VS 2025 (%)
2. US GRAVES’ DISEASE MARKET SHARE BY TREATMENT, 2018 VS 2025 (%)